Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication (Q40771756)

23 September 2017

title

Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication (English)

1 reference

23 September 2017

main subject

anti-retroviral agent

0 references

1 reference

1 reference

1 reference

6

1 reference

23 September 2017

3

Jürg Böni

1 reference

23 September 2017

Leslie R Bisset

1

1 reference

23 September 2017

Hans Lutz

series ordinal

2

1 reference

23 September 2017

Regina Hofmann-Lehmann

series ordinal

4

1 reference

23 September 2017

Ruedi Lüthy

series ordinal

5

1 reference

23 September 2017

language of work or name

1 reference

1 January 2002

1 reference

23 September 2017

1 reference

23 September 2017

volume

53

1 reference

23 September 2017

issue

1

1 reference

23 September 2017

page(s)

35-45

1 reference

Preliminary analysis of the Concorde trial. Concorde Coordinating Committee

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Quantification of in vitro retroviral replication using a one-tube real-time RT-PCR system incorporating direct RNA preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

HAART stopping news: experts examine structured therapy interruption for HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Comparative pharmacokinetics of antiviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Testing anti–HIV drugs in the FIV model

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

How immune-based interventions can change HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

FIV infection of the domestic cat: an animal model for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900190-5

7 January 2021

10.1016/S0166-3542(01)00190-5

Identifiers

DOI

1 reference

23 September 2017

1 reference